Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines: Basel Saturday, October 26, 2024, 14:00 Hrs [IST] This month, the NCCN ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.

Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

The women had early stage breast cancer that was HR-positive and HER2-negative. When compared to chemotherapy, the ribociclib and letrozole were found to be just as effective and better tolerated.

Chen cites Ribociclib, a drug used for many years for those with metastatic breast cancer. Recent studies show that it also significantly improves survival among patients with HR-positive ...

University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments ...

Ribociclib, in combination with the aromatase inhibitor letrozole, improves survival in post-menopausal women with hormone receptor-positive metastatic breast cancer. Breast cancer is a cancer ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...

(Image Credits: Pexels) The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated this month to recommend ribociclib (Kisqali) as a Category 1 preferred ...